Because of the great impact of CYP3A4 on efficacy and toxicity of new drugs, in vitro metabolic experiments with primary hepatocyte or hepatoma cell lines are used to assess and predict xenobiotic metabolism or toxicity at an early stage of drug development. This evidence concerns the gene CYP3A4 and hepatocellular carcinoma.